Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
18,505,347
-
Total 13F shares
-
22,966
-
Share change
-
+22,966
-
Total reported value
-
$209,366
-
Price per share
-
$9.00
-
Number of holders
-
12
-
Value change
-
+$209,366
-
Number of buys
-
12
Institutional Holders of Avalo Therapeutics, Inc. - Common Stock, par value $0.001 per share (AVTX) as of Q4 2023
As of 31 Dec 2023,
Avalo Therapeutics, Inc. - Common Stock, par value $0.001 per share (AVTX) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,966 shares.
The largest 10 holders included
BlackRock Inc., NATIXIS, Tower Research Capital LLC (TRC), FNY Investment Advisers, LLC, ROYAL BANK OF CANADA, MORGAN STANLEY, WELLS FARGO & COMPANY/MN, JPMORGAN CHASE & CO, UBS Group AG, and GROUP ONE TRADING, L.P..
This page lists
12
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.